A cost–utility analysis of dulaglutide versus insulin glargine as third-line therapy for Type 2 diabetes in Canada
Richard F Pollock, Kirsi Norrbacka, Chris Cameron, Leonardo Mancillas-Adame and Mark Jeddi evaluate the cost-effectiveness of dulaglutide 1.5 mg compared with insulin glargine, from the perspective of a Canadian healthcare payer.
There are currently an estimated 424.9 million adults with Type 1 or Type 2 diabetes mellitus (T2DM) worldwide, and the global prevalence is expected to increase to 628.6 million by 2045. The current prevalence of T2DM in Canada is estimated to be 7.6%, and this is predicted to rise alongside the global prevalence. The high prevalence is associated with both a high clinical and economic burden, with diabetes resulting in approximately 15,700 deaths each year in Canada. The economic burden of T2DM was estimated to be CAD 12.2 billion in 2010 and is expected to increase to CAD 16.9 billion by 2020 according to estimates from the Canadian Diabetes Association.
In this study, conducted by researchers from Eli Lilly Canada, Inc. (ON, Canada), Oy Eli Lilly Finland Ab (Helsinki, Finland), Ossian Health Economics and Communications GmbH (Basel, Switzerland) and Cornerstone Research Group, Inc. (ON, Canada), evidence comparing dulaglutide with insulin glargine, identified from a systematic literature review, was utilized to conduct a cost–effectiveness analysis of dulaglutide relative to insulin glargine in patients inadequately controlled with metformin and a sulfonylurea.